WednesdayApr 29, 2026 10:00 am

3 Breakthroughs Showing Quantum Computing is Closer Than Initially Thought

Quantum computing has long been described as a technology perpetually a decade away from practical relevance. However, recent advancements in the technology may bring quantum computing to bear sooner than projected. Three areas of recent progress tell that story: hardware stability, real-world problem-solving, and the resource requirements for error correction. In each, results have arrived sooner than most of the research community predicted.  For starters, continued research into quantum computing has made the technology more stable over time. Qubits are the computing units of quantum machines, capable of representing multiple states simultaneously rather than being limited to a binary value. That capability enables computations classical systems cannot match, but qubits are highly sensitive to interference and can…

Continue Reading

MondayApr 27, 2026 10:00 am

New Molecule May Open New Therapeutic Pathway Against Brain Cancer

Researchers at Brown University Health have identified a molecule that could potentially alter how glioblastoma responds to treatment. Glioblastoma is the deadliest and most prevalent form of brain cancer affecting adults, with a five-year survival rate of just 5%-10%. The molecule, designated miR-181d, is a type of microRNA that appears to work through two separate biological mechanisms. Early findings suggest it could open treatment to patients currently beyond the reach of existing therapies. Brown University Health's study began with an unusual patient group: individuals who survive the disease far longer than their prognosis would predict. The team analyzed hundreds of…

Continue Reading

WednesdayApr 22, 2026 10:00 am

Early Trial Suggests mRNA Vaccine Could Be Effective Against Pancreatic Cancer 

A personalized mRNA vaccine has shown signs of meaningfully extending survival in pancreatic cancer patients. Six-year results from a small but closely tracked clinical trial support that conclusion. The findings are being presented at a major oncology conference in San Diego.  For a disease that has historically resisted immune-based treatments, the data represents a notable step forward in making the disease more responsive to immunotherapy. Donna Gustafson, who in 2020 became the first person to receive such a vaccine for pancreatic cancer, is among those still alive.  Pancreatic cancer is among the most difficult malignancies to detect and treat. No dependable early detection method exists.…

Continue Reading

MondayApr 20, 2026 10:00 am

Encryption Codes at Risk as Quantum Computing Advances

Most digital communications are secured by encryption built on mathematical problems so hard that conventional computers cannot realistically solve them. That assumption could soon be broken by quantum computers that exploit properties of matter at subatomic scales to perform certain calculations far more efficiently than conventional machines ever could.  Such systems may be capable of breaking widely used encryption methods considerably sooner than researchers had expected. Recent results from 2026 have raised concerns about quantum-based security issues in digital spaces.  IBM has built a 120-qubit processor targeting quantum advantage on certain tasks, with a fully fault-tolerant machine on its roadmap for 2029. Google is moving to accelerate its own adoption of quantum-resistant…

Continue Reading

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

Continue Reading

WednesdayApr 15, 2026 11:15 am

Frontieras North America Inc. Launches New Era for Full Coal Utilization

Frontieras notes milestone moment: groundbreaking of facility based on a new industrial model built on extracting the full value of coal. The company’s proprietary approach reframes coal as a versatile raw material capable of producing a wide spectrum of outputs through controlled processing. At the core of this strategy is Frontieras’s FASForm(TM) process, a solid carbon fractionation technology that separates coal into its constituent components. Recent geopolitical conflict and supply disruptions have underscored how vulnerable global energy systems remain, with oil markets particularly exposed to shocks that can ripple through economies and industries almost instantly. The current situation has renewed…

Continue Reading

WednesdayApr 15, 2026 10:00 am

Scientists Discover Brain Cells That Aid Brain Cancer Development

Canadian scientists have made an unexpected finding about glioblastoma, one of the deadliest and hardest-to-treat forms of brain cancer. Cells previously regarded as passive support structures in healthy brain tissue have been found to actively fuel tumor growth through signaling that boosts cancer cell function.  The discovery also points toward a drug already in wide clinical use that may be capable of interrupting that process. Both findings represent meaningful advances in a field that has seen very limited therapeutic progress over several decades.  Glioblastoma carries one of oncology's bleakest prognoses, with survival following diagnosis typically measured in months rather than years. Patients have access to very few effective treatment…

Continue Reading

WednesdayApr 15, 2026 9:45 am

Compact Proton Therapy Delivery Helps Make the Treatment More Accessible for Cancer Patients

For a long time, proton therapy wasn’t available for many cancer patients due to the footprint of traditional proton therapy equipment and the high costs associated with it. However, the size and cost of this equipment is shrinking, opening it up as a more viable treatment option for cancer patients. Liora Technologies, a subsidiary of LIXTE Biotechnology Holdings, Inc., is poised to offer compact, precise, and accessible proton therapy through the innovative Linac for Image Guided Hadron Therapy (“LiGHT”) System. Proton therapy is a specialized cancer treatment that uses precision-guided radiation beams to target and destroy tumors while limiting harm…

Continue Reading

MondayApr 13, 2026 10:00 am

New Urine Test Boosts Forecasting of Treatment Outcomes in Bladder Cancer

Stanford University scientists developed a molecular urine analysis that can distinguish bladder cancer patients who need immunotherapy from those already cured by surgical removal, transforming treatment planning for roughly 60,000 Americans diagnosed yearly with early-stage disease. The screening can detect cancer recurrence months ahead of visible tumor growth, enabling physicians to strengthen interventions for vulnerable patients while avoiding unnecessary treatment for others already disease-free. Early-stage bladder cancer returns frequently despite prompt intervention. Following tumor removal, patients showing high-risk characteristics undergo six weekly BCG immunotherapy bladder treatments aimed at preventing disease comeback. Surgery alone cures some individuals while others experience cancer…

Continue Reading

MondayApr 13, 2026 9:00 am

Rail Vision Ltd. (NASDAQ: RVSN) Targets Growing Billion-Dollar Train Safety Market with AI Obstacle Detection Systems

The global train collision avoidance system market is expected to reach $13.32 billion by 2030, growing at a compound annual growth rate (“CAGR”) of an estimated 15%. Rail Vision’s offerings have been described as AI-powered perception systems that allow rail operators to predict and prevent collisions. The company's two flagship products serve different operational environments but share the same underlying technological architecture. The global train collision avoidance market is undergoing a dramatic transformation, driven by the convergence of advanced camera systems and artificial intelligence. Rail Vision Ltd. (NASDAQ: RVSN, FSE: C80) is positioning itself squarely at the center of that…

Continue Reading

Contact us: (512) 354-7000